DCI directs dental colleges to upload MDS, PG diploma admissions by September 8, details

New Delhi: The Dental Council of India (DCI) has issued a notification directing all dental colleges to upload details of students admitted in MDS and PG Diploma courses for the academic session 2025-26 on the official DCI portal using their allotted login credentials.

As per the revised NEET counseling schedule, the last date for uploading student data and joining is September 8, 2025 (midnight), failing which such admissions will not be recognized under the Dentists Act.

As per the Revised Counseling Schedule issued by the MCC for Online Counseling (Allotment Process) for NEET 50% AIQ and 100% Deemed / Central Universities & State Quota seats for MDS Courses for the academic year – 2025, the MCC has declared the commencement of academic session and last date for joining is 8th September, 2025 for the academic year 2025-26 for MDS Courses.

“Accordingly, the college authorities of all dental colleges are hereby directed to upload the details of students, admitted in MDS / PG Diploma Course(s) at their dental institution for the academic session 2025-26, on DCI Website, using their already allotted login credentials for admissions (https://portal.dciindia.gov.in/login), on or before the last date of joining i.e. is 8th September, 2025 (12:00 midnight), positively. If the college authorities claim any admission after 12:00 midnight of 8th September, 2025, then Section 10B of the Dentists (Amendment) Act, 1993 and/or Section 16A of the Dentists Act, 1948, as the case may be, shall be attracted and it shall be presumed that the college authorities have not admitted such student(s) in MDS / PG Diploma Course(s) at their college for the academic session 2025-26,” the notice read.

In order to ensure smooth uploading the details of students and to avoid the unnecessary delay, undue pressure and technical fault on network, in uploading the details of the students at the last moment of cut-off date, each and every dental institutions shall make its efforts to upload the details of students gradually, immediately after the date of joining of student of each round of counseling, but not later than 12.00 Midnight of 8th September, 2025 in any circumstance. In other words, the college shall not wait for uploading the details of its students for last moment of cut-off date and the details would be uploaded by the college after each round of counseling.

Moreover, it has come to notice that some dental colleges upload the details of students who are not admitted in their college, because of which the college where the student has actually taken admission is unable to upload the details. Colleges are hereby strictly warned to upload the details of only the genuine and bonafide admissions of their college. The onus of furnishing true, correct and authentic information is upon the college concerned and in case of furnishing any wrong / incorrect information, it shall be open to DCI to initiate action against / penalize the college, the notice read.

 Only the uploaded details of students on DCI portal shall be forwarded to the State Dental Councils / Tribunals for addition of MDS / PG Diploma Qualification.

“It is also inform you that only uploaded details of students on DCI Website shall be considered and any detail of students received in any other format viz. e-mail or hard copy shall not be considered at all, therefore, you are requested not to send the subject details through e-mail or post or any other mode. It is also stated that no request for extension of time to upload the above details of students or any other excuse or reason of technical fault, etc. shall be considered, therefore, you are again requested to ensure and make available all arrangements at your end to complete the above task, in time, so as to avoid any litigation and to enable this Council to take necessary action in a time bound manner,” the DCI added.

To view the full official notice click here: https://medicaldialogues.in/pdf_upload/lno4420-public-circular-298561.pdf

Powered by WPeMatico

Caught on Camera: ASHA Worker allegedly slaps Medical Officer at Sikar PHC

Jaipur: In a shocking case of violence against medical professionals, a medical officer at the Primary Health Centre (PHC) in Kochchur, Sikar, was allegedly slapped by an ASHA worker on Friday. The health department has ordered an inquiry, and the accused has been arrested.  

The incident occurred after the doctor issued a notice to the ASHA worker, Santosh Devi from Sub Centre Ganora, for not providing tuberculosis (TB) medicines to a patient. Upset over the notice, she allegedly entered the OPD while the doctor was attending patients, misbehaved with him, and assaulted him.

A video of the incident has gone viral on social media, reportedly showing the ASHA worker shouting at the doctor, misbehaving with him and then suddenly slapping him out of rage. 

Also read- Doctors at Delhi’s Govt Hospital go on strike after MLA allegedly assaults on-duty doctor

Following the incident, the doctor filed a complaint against the ASHA worker at the police station. Based on the complaint, an FIR was registered, and the accused has been arrested. She was presented before the magistrate and was sent to jail.

Reacting strongly, the All Rajasthan In-Service Doctors Association (ARISDA) condemned the attack. An office-bearer told TOI, “Is it possible for someone like an ASHA worker to behave in such a manner? She is not fit to remain in medical service and should be terminated immediately. The state ARISDA is committed to ensuring justice for the doctor.”

The health department has assured that the matter will be investigated thoroughly. “The doctor issued a notice to the ASHA worker for allegedly not providing TB drugs to a patient. She was not happy with the notice served to her. We will investigate the case to find out more details,” said a senior health department official in Sikar. 

Also read- Caught on camera: GMC Srinagar 3rd year PG medico slapped by patient’s attendant

Powered by WPeMatico

Donor, Recipient die after liver transplant; Health Dept issues notice to Sahyadri Hospital

Pune: A woman who had donated a part of her liver to her husband tragically died after he passed away following a transplant surgery at Sahyadri Hospital in Pune, raising serious concerns about post-transplant complications. In response to the incident, the Maharashtra health department has issued a notice to the hospital, an official said.

The transplant took place on August 15 at the Deccan branch of Sahyadri Hospital, a well-known speciality facility. The patient, a 49-year-old man suffering from advanced liver disease, underwent the surgery with a liver donation from his wife.

“We have issued a notice to the hospital and sought details of the recipient and the donor, their video recordings, and the line of treatment. The hospital has been asked to furnish all the details by 10 am on Monday,” he said, reports PTI.

The family had pinned all their hopes on the surgery, even taking out a ₹12 lakh loan to fund the procedure. However, their worst nightmare unfolded just days later. The recipient passed away just two days after the procedure, on August 17. Four days later, on August 21, the donor also died, adding to the family’s heartbreak.

The couple leaves behind two children — a 20-year-old son and a daughter currently studying in Class VII. The recipient had been employed at a private company and was facing financial difficulties in recent times.

Also Read:Patient dies after alleged expired glucose injection: Consumer court clears nursing home of negligence

Speaking to the Indian Express, the brother of the deceased woman said, “This year, my brother-in-law found it difficult to pay the annual fee of Rs 40,000 for his daughter’s school. The management allowed him to pay it in instalments.” The loan, he said, has to be repaid, which is now another cause of concern for the family.

He said they had chosen Sahyadri Hospital because it is considered a specialty hospital, and questioned how the donor could have died and what went wrong in the case of his brother-in-law. A post-mortem was conducted at Sassoon Hospital, and once the report is received, they plan to approach an expert committee to investigate possible medical negligence. 

He mentioned that his sister, a homemaker, did not have diabetes or hypertension, and that his brother-in-law had stopped drinking nearly 10 years ago. The surgery was conducted on August 15, and within a few hours, his brother-in-law passed away. While the family had been mentally prepared for his death due to his critical condition, his sister’s death came as a complete shock. After the surgery, she was shifted to the ICU for observation and was never discharged. Doctors had stated prior to the surgery that there was a 5% risk, but the family has now lost her.

Speaking to TOI, he said, “We had not informed our sister about her husband’s death as it would have traumatised her. Her condition deteriorated on Thursday night, and she was put on dialysis. We were informed about her death on Friday afternoon. We are not convinced by the doctors’ answers. We are waiting for the post-mortem report. Once we get it, we will file a police complaint and submit all documents to the medical negligence committee for investigation.”

In a statement issued on Saturday, Sahyadri Hospital said, “We deeply empathise with the patients’ family in this time of immense loss. Liver transplant is one of the most complex procedures, and in this case, the recipient was a high-risk patient with end-stage liver disease. As per protocol, the family was fully counselled about the risks in advance. The surgeries were carried out following standard medical protocols. Unfortunately, the recipient developed cardiogenic shock after the transplant and could not be revived despite all efforts. The donor initially recovered well, but later on the sixth-postoperative day, developed sudden hypotensive shock with subsequent multi-organ dysfunction, which could not be controlled even with advanced treatment. We remain committed to providing the highest standards of care and extend our deepest empathy to the bereaved family during this tragic time,” reports Indian Express.

Dr. Yellapa Jadhav, the medical superintendent of Sassoon General Hospital, said that when a family suspects medical negligence, they must file a complaint with the police. He explained that only after such a complaint can the police request an enquiry, upon which the hospital would initiate an investigation into the case.

Also Read:Woman, newborn die during botched delivery at nursing home; 3 arrested

Powered by WPeMatico

Genetic testing of IVF embryos can help women over 35 conceive faster

Genetic testing of IVF-created embryos could help more women over 35 have a baby in less time, a clinical trial by researchers from King’s College London, King’s College Hospital, and King’s Fertility has found.

Powered by WPeMatico

Evidence, not ideology, must guide preventive health care, say experts

A recent review of the Canadian Task Force on Preventive Health Care underscores the need for expert bodies to produce evidence-based guidance and that Canada should ensure a renewed task force is adequately funded and supported, argues a commentary in the Canadian Medical Association Journal.

Powered by WPeMatico

New guideline offers menu of options to help people quit smoking tobacco

Tobacco smoking is the number one cause of preventable disease and death in Canada; it is highly addictive and hard to stop. Recognizing these challenges, a new guideline from the Canadian Task Force on Preventive Health Care provides a menu of effective options to help people quit smoking, with behavioral and medication options and a natural health product that can be tailored and combined for personal choice.

Powered by WPeMatico

Kids in disadvantaged zip codes face up to 20 times higher odds of gun injuries, study reveals

Children residing in “very low-opportunity” neighborhoods are up to 20 times more likely to be hospitalized for gun injuries than those living in the most advantaged areas, reports a new multi-state study published in Pediatrics titled “Pediatric Firearm-Related Hospital Encounters by Child Opportunity Index Level.”

Powered by WPeMatico

Survey reveals people are not aware knee and groin pain can be signs of hip problems

Having a hard time bending over to put your shoes on? Experiencing pain in the knees, groin, thigh or back? A survey by The Ohio State University Wexner Medical Center reveals many people don’t realize these symptoms can mean there’s a problem in the hip.

Powered by WPeMatico

The Forgotten Insulin Sensitizer: Revisiting Pioglitazone for Metabolically Unhealthy Non-Obese (MUNO) Indians with T2DM

MUNO Indian Phenotype: A Silent High-Risk Candidate

The Metabolically Unhealthy Non-Obese (MUNO) phenotype is a silent but high-risk profile, especially common among South Asians. Despite a normal BMI, these individuals have markedly higher visceral and liver fat, increased carotid intima-media thickness (CIMT), and reduced insulin sensitivity and secretion, which significantly elevates the risk of T2D and CVD. (1) An Indian study (n= 2,560) found that 97.1% of normal-BMI adults were metabolically unhealthy, highlighting the urgency of early identification and addressing the clinical needs of MUNO. (2)

Pioglitazone: Addressing the Pathophysiological Needs Associated with MUNO

Pioglitazone enhances insulin sensitivity by activating PPAR-γ and AMPK pathways, thereby promoting peripheral glucose uptake, improving hepatic insulin action, and reducing endogenous glucose production. It also improves adipose tissue function, lowers triglycerides, raises HDL, and shifts fat from visceral to subcutaneous depots—mechanistically aligning with the core metabolic defects seen in the MUNO phenotype.(3,4)

Clinical Evidence with Pioglitazone: Glycemic and Beyond-Glycemic Benefits

Effect on HbA1c, Lipid & Insulin Function: A 23-week, multicenter, double-blind RCT enrolled 197 patients with T2DM (HbA1c ≥8%, FPG >140 mg/dL, C-peptide >1 ng/mL) to assess the efficacy and safety of pioglitazone vs. placebo. Pioglitazone significantly reduced HbA1c (−1.37%, p=0.0001), FPG (−57.5 mg/dL), HOMA-IR (−12.4%), and triglycerides (−16.6%), while increasing HDL-C (+12.6%) and β-cell function [+47.7%]. (5)

Effect on Progression of NAFLD: In an 18-month randomized, double-blind, placebo-controlled trial (n=101) with biopsy-proven NASH and prediabetes or T2DM, pioglitazone reduced the NAFLD activity score—defined as a ≥2-point reduction in at least two histologic categories without worsening of fibrosis (primary endpoint)—in 58% of patients (p<0.001) and achieved NASH resolution in 51% of the cases. It also improved fibrosis score (−0.5) and reduced hepatic fat by ~63% (absolute −12%). Benefits persisted through 36 months. (6)

Effect on Cardiovascular Risk: In the IRIS trial, 3,876 patients without diabetes but with insulin resistance and a recent ischemic stroke or TIA were randomized to receive pioglitazone or placebo over a median of 4.8 years. Pioglitazone reduced the risk of stroke or myocardial infarction by 24% (HR 0.76, p=0.007). It also achieved a 52% relative risk reduction in new-onset diabetes [HR 0.48, p<0.001]. (7)

Safety of Pioglitazone

The above studies, which demonstrated the clinical benefits of pioglitazone, also provide important insights into its safety profile. While higher rates of weight gain, edema, and fractures were observed compared to placebo, the absolute risk remained low, and no significant increase in heart failure or cancer risk was reported.Long-term use revealed no new safety signals or major drug-related adverse events, supporting its acceptable safety profile in appropriately selected patients. (5,6,7)

Dosing considerations: For adults and elderly patients, initiate treatment at 15-30 mg orally once daily, with possible 15 mg incremental increases based on therapeutic response, not exceeding a maximum daily dose of 45 mg.

Contraindications: Pioglitazone is contraindicated in patients with hypersensitivity to the drug, diabetic ketoacidosis, heart failure (NYHA Class III-IV in the US, any class in Canada), fluid overload, active or previous bladder cancer, high fracture risk, active liver disease with elevated transaminases, and pregnancy. It should not be initiated in patients with hypoglycemia requiring frequent monitoring, and is considered potentially inappropriate for elderly patients with heart or kidney failure.(8) Its cardiovascular benefits must be balanced against fracture risk, especially in postmenopausal women. (9) Mild anemia may occur due to hemodilution (10), and fluid retention may worsen or exacerbate existing or developing heart failure. (11)

Case-Based Scenarios: When to Consider?

A 41-year-old man with a normal BMI (22.2 kg/m2) presents with newly diagnosed T2DM. His fasting insulin is elevated at 22 µIU/mL, and HOMA-IR is calculated at 5.9, indicating significant insulin resistance. An abdominal ultrasound shows grade I hepatic steatosis consistent with mild fatty liver. With no hypertension or CVD, his profile reflects early metabolic dysfunction. Pioglitazone may be considered in this case to improve insulin sensitivity and prevent the progression of MASLD.

MASLD & T2DM: Guidelines Spotlight

  • Indian Diabetologists’ Consensus on MASLD (2025): Suggested considering pioglitazone as an anti-hyperglycemic agent in patients with T2DM and MASLD, especially when individualized therapy is needed or lifestyle interventions are insufficient, due to its potential hepatic benefits. (12)
  • Global MASH Council Consensus (2025): Suggests considering pioglitazone for type 2 diabetes in individuals with or without MASH, but not as a MASH-targeted therapy. (13)
  • ADA (2025): Recommends pioglitazone, a GLP-1 RA, or dual GIP/GLP-1 RA for glycemic control in adults with T2DM and biopsy-confirmed MASH or high fibrosis risk, given their potential benefits on MASH. (14)
  • AASLD (2023): States that pioglitazone improves NASH and may be considered for patients with NASH in the context of T2DM. (15)
  • AACE (2023): Suggest considering pioglitazone in T2D patients with comorbidities such as stroke, NAFLD, or prediabetes. Pioglitazone may also help improve triglyceride levels and reduce the risk of recurrent stroke in those with prior TIA or stroke. (16)
  • RSSDI (2022): Recommends pioglitazone for secondary prevention in patients with stroke or TIA, and also for diabetes management in elderly individuals. (17)

Key Takeaways

  • Nearly 97% of normal-BMI Indian adults are metabolically unhealthy, underlining the need to identify and manage the MUNO T2D phenotype early.
  • Pioglitazone directly targets insulin resistance, adipose redistribution, and hepatic steatosis, making it a mechanistically rational therapy for MUNO patients.
  • Evidence supports both glycemic (HbA1c, HOMA-IR) and non-glycemic (NASH resolution, CVD risk reduction) benefits.
  • Supported by global and Indian guidelines, like the Indian Diabetologists’ Consensus (2025), Global MASH Council (2025), ADA (2025), AASLD (2023), AACE (2023), and RSSDI (2022), pioglitazone remains a relevant but underutilized option in specific patient profiles (T2DM, MASLD, and stroke-risk patients.)
  • Pioglitazone-based FDCs offer a practical approach for addressing the silent metabolic dysfunction in MUNO, especially when dual therapy fails to target insulin resistance effectively.

References:

1. Stefan, Norbert et al. “Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans.” Cell metabolism vol. 26,2 (2017): 292-300. doi:10.1016/j.cmet.2017.07.008

2. Sivanantham, Parthibane et al. “High prevalence of abdominal obesities and metabolically unhealthy individuals in a highly urbanized district of India: findings of a cross-sectional survey in Puducherry.” Family practice vol. 40,2 (2023): 282-289. doi:10.1093/fampra/cmac082

3. Coletta, D K et al. “Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial.” Diabetologia vol. 52,4 (2009): 723-32. doi:10.1007/s00125-008-1256-9

4. Sourij H, Wascher TC. Pioglitazone in the management of Type 2 diabetes and beyond. Drugs. 2010;70(8):925–954.

5. Rosenblatt, S et al. “The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.” Coronary artery disease vol. 12,5 (2001): 413-23. doi:10.1097/00019501-200108000-00011

6. Cusi, Kenneth et al. “Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.” Annals of internal medicine vol. 165,5 (2016): 305-15. doi:10.7326/M15-1774

7. Kernan, Walter N et al. “Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.” The New England journal of medicine vol. 374,14 (2016): 1321-31. doi:10.1056/NEJMoa1506930

8. Singh G, Can AS, Correa R. Pioglitazone. [Updated 2023 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544287/

9. Azhari, Hala F, and Jesse Dawson. “Clinical implications of fracture severity risk with pioglitazone: a systematic review and meta-analysis of clinical randomized trials.” Frontiers in pharmacology vol. 16 1357309. 6 Mar. 2025, doi:10.3389/fphar.2025.1357309

10. Antoniadou, Christina et al. “Anemia in diabetes mellitus: Pathogenetic aspects and the value of early erythropoietin therapy.” Metabolism open vol. 25 100344. 4 Jan. 2025, doi:10.1016/j.metop.2024.100344

11. Kavanagh, Kylie et al. “Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes.” Metabolism: clinical and experimental vol. 59,6 (2010): 914-20. doi:10.1016/j.metabol.2010.02.010

12. Zargar, Abdul Hamid et al. “Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists’ perspective.” Diabetes, obesity & metabolism vol. 27 Suppl 4,Suppl 4 (2025): 3-20. doi:10.1111/dom.16496

13. Younossi, Zobair M et al. “Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.” Gastroenterology, S0016-5085(25)00632-8. 11 Apr. 2025, doi:10.1053/j.gastro.2025.02.044

14. American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care 1 January 2025; 48 (Supplement_1): S181–S206. https://doi.org/10.2337/dc25-S009

15. Rinella, Mary E et al. “AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.” Hepatology (Baltimore, Md.) vol. 77,5 (2023): 1797-1835. doi:10.1097/HEP.0000000000000323

16. Samson, Susan L et al. “American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 29,5 (2023): 305-340. doi:10.1016/j.eprac.2023.02.001

17. RSSDI (2022). RSSDI Clinical Practice Recommendations 2022: Summary Document for Training. Research Society for the Study of Diabetes in India (RSSDI).

Abbreviations: MUNO: Metabolically Unhealthy Non-Obese, T2DM: Type 2 Diabetes Mellitus, CVD: Cardiovascular Disease, PPAR-γ: Peroxisome Proliferator-Activated Receptor Gamma, AMPK: AMP-Activated Protein Kinase, HbA1c: Hemoglobin A1c, FPG: Fasting Plasma Glucose, HOMA-IR: Homeostasis Model Assessment of Insulin Resistance, HDL-C: High-Density Lipoprotein Cholesterol, NAFLD: Non-Alcoholic Fatty Liver Disease, NASH: Non-Alcoholic Steatohepatitis, MASLD: Metabolic Dysfunction-Associated Steatotic Liver Disease, MACCE: Major Adverse Cardiovascular and Cerebrovascular Events, CKD: Chronic Kidney Disease, ESRD: End-Stage Renal Disease, TIA: Transient Ischemic Attack, RCT: Randomized Controlled Trial, ADA: American Diabetes Association, AASLD: American Association for the Study of Liver Diseases, AACE: American Association of Clinical Endocrinology, RSSDI: Research Society for the Study of Diabetes in India

Powered by WPeMatico

Shingrix Vaccine Cuts Risk of Herpes Zoster Ophthalmicus, Heart Attack, and Stroke in Adults 50+: Study

A new study published in the journal of Clinical Infectious Diseases showed that in addition to reducing the incidence of herpes zoster ophthalmicus (HZO) by 72.9%, the recombinant herpes zoster vaccine (Shingrix) was associated with a decreased risk of hospitalization for acute myocardial infarction (MI) and stroke in patients 50 years of age and older.

A prevalent illness in older persons, herpes zoster (HZ) is brought on by the reactivation of the latent varicella zoster virus and can result in serious morbidity and a reduced quality of life. Herpes zoster ophthalmicus, one of its most severe forms, can cause long-term eye problems and vision loss. The adjuvanted recombinant zoster vaccine (RZV), which provides strong and long-lasting protection against HZ across age groups, has revolutionized preventative measures. 

Thereby, to optimize preventive treatment and guide vaccination programs for older populations at increased risk for cardiovascular and infectious problems, it is imperative to comprehend these protective benefits. This study assessed the relationship between recombinant zoster vaccine and risk for hospitalized stroke, hospitalized acute myocardial infarction (AMI), and hospitalized HZO in adults aged ≥50 years (YoA).

Using sex, age, race/ethnicity, and index date (date of second dose among vaccinated; date of unvaccinated match assigned same date), this research matched adults ≥50 YoA who received 2 doses of RZV 4 weeks–6 months apart between 01 April 2018 and 31 December 2020 1:4 to RZV-unvaccinated individuals.

The follow-up period began on the index date and terminated on December 31, 2022, or upon receiving the zoster vaccination, membership termination, or death, whichever occurred first. ICD-10 codes were used to identify inpatient AMI and stroke, whereas natural language analysis of clinical notes was used to identify HZO. 

The median age was 68 years (range: 50, 108), 59.0% of the 102,766 2-dose RZV-vaccinated and 411,064 unvaccinated people were female, and 57.1% were non-Hispanic White.

When comparing RZV-vaccinated and unvaccinated persons, the aHRs (95% CI) for inpatient stroke, hospitalized AMI, and HZO were 0.575 (0.533, 0.619), 0.720 (0.588, 0.881), and 0.271 (95% CI: 0.222, 0.330), respectively. 72.9% (67.0%, 77.8%) was the adjusted RZV efficacy against HZO. Overall, two RZV dosages were linked to a decreased incidence of HZO, AMI, and stroke in persons aged ≥50 years.

Source:

Rayens, E., Sy, L. S., Qian, L., Wu, J., Ackerson, B. K., Luo, Y., Zheng, C., Cheng, Y., Vega Daily, L. I., Song, J., Takhar, H. S., Ku, J. H., Cohen, R. A., Yun, H., Oraichi, D., Seifert, H., & Tseng, H.-F. (2025). Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged ≥50 years. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciaf440

Powered by WPeMatico